Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Medhat S Gabriel

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal of Nuclear Medicine Technology|March 11, 2017
Managing Written Directives: A Software Solution to Streamline WorkflowRobert H Wagner, Bital Savir-Baruch, Medhat S Gabriel, et al.
Journal of Nuclear Medicine Technology|July 15, 2017
Proof of Concept: Design and Initial Evaluation of a Device to Measure Gastrointestinal Transit TimeRobert H Wagner, Bital Savir-Baruch, James R Halama, et al.
Molecular Imaging and Biology|September 4, 2021
Positivity Rate of [<sup>18</sup>F]Fluciclovine PET/CT in Patients with Suspected Prostate Cancer Recurrence at PSA Levels Below 1 ng/mLJad El Bulbul, Damian Grybowski, Petra Lovrec, et al.
Urologic Oncology|June 23, 2022
Effect of hormonal therapy on <sup>18</sup>F-fluciclovine PET/CT in the detection of prostate cancer recurrence, localization of metastatic disease, and correlation with prostate-specific antigenJad El Bulbul, Abdulrahman Hashem, Damian Grybowski, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal of Nuclear Medicine Technology|March 11, 2017
Managing Written Directives: A Software Solution to Streamline WorkflowRobert H Wagner, Bital Savir-Baruch, Medhat S Gabriel, et al.
Journal of Nuclear Medicine Technology|July 15, 2017
Proof of Concept: Design and Initial Evaluation of a Device to Measure Gastrointestinal Transit TimeRobert H Wagner, Bital Savir-Baruch, James R Halama, et al.
Molecular Imaging and Biology|September 4, 2021
Positivity Rate of [<sup>18</sup>F]Fluciclovine PET/CT in Patients with Suspected Prostate Cancer Recurrence at PSA Levels Below 1 ng/mLJad El Bulbul, Damian Grybowski, Petra Lovrec, et al.
Urologic Oncology|June 23, 2022
Effect of hormonal therapy on <sup>18</sup>F-fluciclovine PET/CT in the detection of prostate cancer recurrence, localization of metastatic disease, and correlation with prostate-specific antigenJad El Bulbul, Abdulrahman Hashem, Damian Grybowski, et al.
Pageof 1